9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $377M | -$78M | 50.7% | -36.2% | -$76M | — | $183M |
| 2024 | $313M | -$209M | 42.6% | -70.6% | -$69M | — | $226M |
| 2023 | $245M | -$205M | 36.6% | -88.6% | -$170M | — | $286M |
| 2022 | $204M | -$218M | 41.4% | -115.3% | -$226M | — | $379M |
| 2021 | $132M | -$152M | 39.1% | -115.4% | -$139M | — | $466M |
| 2020 | $90M | -$140M | 31.8% | -155.5% | -$152M | $4M | $94M |
| 2019 | $54M | -$108M | 12.8% | -200.1% | -$103M | $8M | $47M |
| 2018 | $25M | -$71M | -26.6% | -277.5% | -$70M | $10M | $81M |
| 2017 | $11M | -$59M | -123.1% | -543.2% | -$58M | — | $31M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $111M | -$44M | 51.6% | -41.4% | -$25M | — | $123M |
| Dec '25 | $104M | -$31M | 52.0% | -31.7% | -$35M | — | $149M |
| Sep '25 | $99M | -$27M | 51.3% | -30.2% | -$24M | — | $183M |
| Jun '25 | $96M | $20M | 53.4% | -31.4% | -$11M | — | $201M |
| Mar '25 | $93M | -$39M | 49.6% | -44.8% | -$17M | — | $210M |
| Dec '24 | $89M | -$32M | 48.3% | -39.1% | -$24M | — | $221M |
| Sep '24 | $85M | -$35M | 45.1% | -42.5% | -$17M | — | $226M |
| Jun '24 | $81M | -$86M | 43.3% | -109.2% | -$7M | — | $239M |
| Mar '24 | $75M | -$45M | 41.0% | -64.9% | -$20M | — | $243M |
| Dec '23 | $71M | -$43M | 40.5% | -65.7% | -$24M | — | $266M |
| Sep '23 | $67M | -$46M | 36.6% | -74.9% | -$23M | — | $286M |
| Jun '23 | $64M | -$57M | 34.4% | -95.4% | -$28M | — | $307M |
| Mar '23 | $60M | -$59M | 30.8% | -102.4% | -$53M | — | $315M |
| Dec '22 | $54M | -$42M | 45.7% | -82.3% | -$66M | — | $317M |
| Sep '22 | $57M | -$51M | 44.9% | -99.2% | -$18M | — | $379M |
| Jun '22 | $56M | -$61M | 44.8% | -109.0% | -$75M | — | $376M |
| Mar '22 | $48M | -$61M | 38.3% | -126.3% | -$74M | — | $408M |
| Dec '21 | $42M | -$46M | 35.6% | -133.1% | -$59M | — | $192M |
| Sep '21 | $38M | -$41M | 40.7% | -104.9% | -$43M | — | $466M |
| Jun '21 | $35M | -$40M | 40.2% | -120.3% | -$35M | — | $475M |
How the market has priced TWST against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Twist Bioscience Corp's revenue has grown 33.1% per year. These are computed facts, not advice.
As of FY2025, Twist Bioscience Corp reported — of total debt against $183M of cash.
In FY2025, gross margin was 50.7%, operating margin -36.2%, and net margin -20.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.